Richard Rodgers
Direktor/Vorstandsmitglied bei ARDELYX, INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| David Mott | M | 58 | 15 Jahre | |
| George Kemble | M | 63 | 13 Jahre | |
| John Trizzino | M | 64 | 10 Jahre | |
| Elizabeth Grammer | F | 60 | 12 Jahre | |
| James Young | M | 71 | 14 Jahre | |
| Merdad Parsey | M | 61 | 14 Jahre | |
| Justin Renz | M | 52 | 4 Jahre | |
| Beth Seidenberg | M | 67 | 17 Jahre | |
| David Happel | M | 62 | 2 Jahre | |
| Mike Raab Raab | M | 59 | 15 Jahre | |
| Amy Rabourn | F | 44 | 5 Jahre | |
| Cam Gallagher | M | 54 | 5 Jahre | |
| John Jacobs | M | 57 | 1 Jahre | |
| Bernhard Hoffmann | M | 68 | 6 Jahre | |
| Robert Felsch | M | - | 4 Jahre | |
| Laura Williams | M | 61 | 4 Jahre | |
| Muna Bhanji | F | 61 | 3 Jahre | |
| George Magrath | M | 40 | 1 Jahre | |
| Erik Sims | M | - | 3 Jahre | |
| Brian Rosen | M | - | 9 Jahre | |
| Jay Pepose | M | 69 | 3 Jahre | |
| Sean Ainsworth | M | 56 | 6 Jahre | |
| Robert B. Bazemore | M | 56 | 8 Jahre | |
| Caitlin Lowie | F | - | 2 Jahre | |
| Silvia Taylor | F | - | 4 Jahre | |
| James Kelly | M | 58 | 3 Jahre | |
| Elizabeth Rozek | F | 53 | 1 Jahre | |
| Onaiza Cadoret-Manier | F | 60 | 4 Jahre | |
| James Armitage | M | 77 |
MGI PHARMA, Inc.
 MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | 14 Jahre |
| Gale Smith | M | - | 20 Jahre | |
| William Bertrand | M | 59 | 9 Jahre | |
| Susan Benton | F | 59 | 4 Jahre | |
| Gregg Alton | M | 58 | 4 Jahre | |
| Richard Douglas | M | 71 | 14 Jahre | |
| Jan Lundberg | M | 70 | 6 Jahre | |
| Mark Joseph Casey | M | 60 | 1 Jahre | |
| Rachel King | F | 64 | 6 Jahre | |
| James Manuso | M | 75 | 5 Jahre | |
| Margaret McGlynn | F | 64 | 4 Jahre | |
| Nirav Jhaveri | M | 46 | - | |
| Raburn Mallory | M | - | 4 Jahre | |
| Troy Morgan | M | - | 3 Jahre | |
| Denny Kim | M | - | 3 Jahre | |
| Johann Bono | M | - | - | |
| Ursula Matulonis | F | - | - | |
| Duncan Jodrell | M | - | - | |
| Seth Toback | M | - | 4 Jahre | |
| Barbara Withers | F | - | - | |
| Erika Schultz | F | - | - | |
| Ronil Patel | M | - | 3 Jahre | |
| Arnold Lewis Oronsky | M | 83 | 13 Jahre | |
| Frank D. Czworka | M | 55 | 4 Jahre | |
| Henrietta Ukwu | M | 64 | 3 Jahre | |
| Drey Coleman | F | - | - | |
| Anne-Marie O'Farrell | M | - | 11 Jahre | |
| Robert Blanks | M | 64 | 11 Jahre | |
| Filip Dubovsky | M | 59 | 4 Jahre | |
| Biegie Lee | M | - | 7 Jahre | |
| Chris Dunne | M | - | 14 Jahre | |
| David Rosenbaum | M | 63 | 14 Jahre | |
| Gaeton Biscardi | M | - | - | |
| Mitchell Brigell | M | - | - | |
| Joseph Schachle | M | 59 | 1 Jahre | |
| Iksung Cho | M | - | 9 Jahre | |
| Timothy Jon Hahn | M | 60 | 4 Jahre | |
| Alison Chartan | F | - | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mary Lynne Hedley | M | 61 |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | 16 Jahre |
| Douglas Swirsky | M | 54 |
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | 2 Jahre |
| Lonnie Moulder | M | 66 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 10 Jahre |
| Mina Sooch | F | 56 | 5 Jahre | |
| Chang Ho Ahn | M | 72 |
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | 16 Jahre |
| Gordon Ringold | M | 73 | 14 Jahre | |
| Mark E. Kaufmann | M | 56 | 9 Jahre | |
| Stanley Erck | M | 76 | 14 Jahre | |
| Joseph Oriti | M | 44 | - | |
| John Herrmann | M | 58 | 13 Jahre | |
| Anthony Rimac | M | 60 | 1 Jahre | |
| Patrick Soon-Shiong | M | 71 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 3 Jahre |
| Dominique Charmot | M | 69 | 7 Jahre | |
| Richard R. Roscitt | M | 72 | 2 Jahre | |
| Tae Heum Jeong | M | 53 |
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | 15 Jahre |
| Edward C. English | M | 57 | 5 Jahre | |
| Peter G. Schultz | M | 67 | 8 Jahre | |
| Jennifer Davis Ruff | F | - | 5 Jahre | |
| Jill Hoyt | F | - | 15 Jahre | |
| Rakesh Soni | M | 68 |
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | 7 Jahre |
| Si Moon Hwang | M | 55 |
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | 3 Jahre |
| Keith Santorelli | M | - | - | |
| Annalisa Jenkins | M | 58 | 5 Jahre | |
| Geoffrey A. Block | M | 58 | 4 Jahre | |
| Paul Walker | M | 49 | 4 Jahre | |
| Jeffrey W. Jacobs | M | 61 | 13 Jahre | |
| Eric P. Loukas | M | 67 |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | 7 Jahre |
| Jean M. Fréchet | M | - | 7 Jahre | |
| David Martin McIntosh | M | 65 |
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | 11 Jahre |
| David Collier | M | 61 | - | |
| William Cadogan | M | 75 | 14 Jahre | |
| Russell Wilson | M | 64 | 12 Jahre | |
| Peter David Suzdak | M | 65 |
Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | 5 Jahre |
| David F. Fisher | M | 75 | 5 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 50 | 50,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Richard Rodgers
- Persönliches Netzwerk
